LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme

Authors

Institutions

Publication Details

Journal
BMJ Open
Published
2025-11-01
DOI
https://doi.org/10.1136/bmjopen-2025-106094
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme

Hiie Soeorg, Kristen Buck, Tambet Teesalu, Katrin Kaarna et al.
BMJ Open
Glioma Diagnosis and Treatment
article

LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme

Hiie Soeorg, Kristen Buck, Tambet Teesalu, Katrin Kaarna, William K. Sietsema, Kersti Oselin, Kadri Toome, Jana Lass, Lenne‐Triin Körgvee, Johannes Pärtel Truusalu
article en

Abstract

No abstract available for this paper.
BMJ OpenVol. 15(11)
University of California, Santa Barbara (US), Tartu University Hospital (EE), North Estonia Medical Centre (EE), Reproductive Medicine Associates of New Jersey (US), University College London (GB), University of Tartu (EE)
Openalex Percentile: Top 50%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.